CompletedNot Applicable

Psychological Morbidity and Facial Volume in HIV Lipodystrophy: Quantification of Treatment Outcome

50 participantsStarted 2006-08

Plain-language summary

The hypotheses of this study were that: 1. HIV lipodystrophy is associated with psychological morbidity relating to body image, anxiety and depression. 2. Treatment of HIV lipodystrophy using autologous fat transfer, polylactic acid or Bio-alcamid, is associated with an improvement in psychological morbidity and anatomical volume of treated areas. 3. The DI3D system is a valid and reproducible method of recording and measuring facial 3-D volume.

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * HIV facial lipoatrophy * concurrent antiretrovirals Exclusion Criteria: * known psychological disorder * skin allergies * significant medical problems precluding anaesthesia

What they're measuring

measurement of 3-D facial volume

Timeframe: 2 years

Trial details

NCT IDNCT01359917

SponsorNHS Lothian

Sponsor typeOTHER_GOV

Study typeOBSERVATIONAL

Primary completion2009-07

View on ClinicalTrials.gov More HIV-Associated Lipodystrophy Syndrome trials